• Please log in or register to access this feature.

Research Article

You have full text access to this OnlineOpen article

Effects of Intravenous Pamidronate Treatment in Infants With Osteogenesis Imperfecta: Clinical and Histomorphometric Outcome†

  1. Craig FJ Munns‡,
  2. Frank Rauch MD*,
  3. Rose Travers,
  4. Francis H Glorieux

Article first published online: 21 FEB 2005

DOI: 10.1359/JBMR.050213

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 20, Issue 7, pages 1235–1243, July 2005

Additional Information

How to Cite

Munns, C. F., Rauch, F., Travers, R. and Glorieux, F. H. (2005), Effects of Intravenous Pamidronate Treatment in Infants With Osteogenesis Imperfecta: Clinical and Histomorphometric Outcome. J Bone Miner Res, 20: 1235–1243. doi: 10.1359/JBMR.050213

Author Information

  1. Genetics Unit, Shriners Hospital for Children and McGill University, Montréal, Québec, Canada

  1. ‡

    The Children's Hospital at Westmead; Westmead, New South Wales, Australia

*Genetics Unit, Shriners Hospital for Children, 1529 Cedar Avenue, Montréal, Québec H3G 1A6, Canada

  1. †

    The authors have no conflict of interest.

Publication History

  1. Issue published online: 4 DEC 2009
  2. Article first published online: 21 FEB 2005
  3. Manuscript Accepted: 18 FEB 2005
  4. Manuscript Revised: 3 FEB 2005
  5. Manuscript Received: 25 AUG 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1673K)

REFERENCES

  • 1
    Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16: 101–116.
  • 2
    Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM 2000 Normative data for iliac bone histomorphometry in growing children. Bone 26: 103–109.
  • 3
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947–952.
  • 4
    Astrom A, Soderhall S 2002 Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86: 356–364.
  • 5
    Zacharin M, Bateman J 2002 Pamidronate treatment of osteogenesis imperfecta-lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 15: 163–174.
  • 6
    Rauch F, Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110: 1293–1299.
  • 7
    Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85: 1846–1850.
  • 8
    Astrom E, Soderhall S 2002 Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86: 356–364.
  • 9
    Chien YH, Chu SY, Hsu CC, Hwu WL 2002 Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. J Inherit Metab Dis 25: 593–595.
  • 10
    Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML 2003 Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111: 573–578.
  • 11
    DiMeglio LA, Ford L, McClintock C, Peacock M 2004 Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 35: 1038–1045.
  • 12
    Zeitlin L, Fassier F, Glorieux FH 2003 Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B 12: 77–87.
  • 13
    Feldman AB, Haley SM, Coryell J 1990 Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther 70: 602–610.
  • 14
    Bleck EE 1981 Nonoperative treatment of osteogenesis imperfecta: Orthotic and mobility management. Clin Orthop 159: 111–122.
  • 15
    Greulich WW, Pyle SI 1959 Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd ed. Stanford University Press, Stanford, CA, USA.
  • 16
    Spencer RP, Sagel SS, Garn SM 1968 Age changes in five parameters of metacarpal growth. Invest Radiol 3: 27–34.
  • 17
    Smith-Bindman R, Cummings SR, Steiger P, Genant HK 1991 A comparison of morphometric definitions of vertebral fracture. J Bone Miner Res 6: 25–34.
  • 18
    Salle BL, Braillon P, Glorieux FH, Brunet J, Cavero E, Meunier PJ 1992 Lumbar bone mineral content measured by dual energy X-ray absorptiometry in newborns and infants. Acta Paediatr 81: 953–958.
  • 19
    Rauch F, Plotkin H, Zeitlin L, Glorieux FH 2003 Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate therapy. J Bone Miner Res 18: 610–614.
  • 20
    Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH 2003 Osteogenesis imperfecta types I, III and IV: Effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88: 986–992.
  • 21
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595–610.
  • 22
    Fazzalari NL, Moore AJ, Byers S, Byard RW 1997 Quantitative analysis of trabecular morphogenesis in the human costochondral junction during the postnatal period in normal subjects. Anat Rec 248: 1–12.
  • 23
    Mayahara M, Sasaki T 2003 Cellular mechanism of inhibition of osteoclastic resorption of bone and calcified cartilage by long-term pamidronate administration in ovariectomized mature rats. Anat Rec 274A: 817–826.
  • 24
    Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S 2003 Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457–463.
  • 25
    Halasy-Nagy JM, Rodan GA, Reszka AA 2001 Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29: 553–559.
  • 26
    Munns CF, Rauch F, Mier RJ, Glorieux FH 2004 Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 35: 231–234.
  • 27
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15: 613–620.
View Full Article (HTML) Get PDF (1673K)